A Trump administration staffer described as playing a significant role in its drug pricing plan is leaving his current advisory role after less than a year.
In a statement Monday, Health and Human Services Secretary Alex Azar said that John O’Brien would be stepping down as senior adviser to the secretary on drug pricing reform, a position to which he was appointed in December 2018. Current Principal Deputy Director of the Center for Medicare John Brooks will take over the role.
O’Brien has served in HHS since March 2017, having most recently worked as vice president for public policy at CareFirst BlueCross BlueShield.
It was not immediately clear what O’Brien’s reason for leaving was, or what his next role will be. Reached via social media, O’Brien directed inquiries to an HHS public affairs officer, who did not immediately respond to a request for comment.
Azar described O’Brien as a “key architect” of the administration’s drug-pricing plan, a collection of policy proposals released last year that it said would reduce drug costs, and said O’Brien’s efforts had reduced out-of-pocket drug costs and would continue to do so.
“John O’Brien’s time at HHS will leave a legacy of lasting improvements to American healthcare, including the way that Americans pay for prescription drugs,” Azar said in the statement. From the beginning of President Trump’s administration, John led policy research, analysis and development on a number of important issues, including strengthening the Medicare program for our seniors and addressing the effects of the Affordable Care Act.”
Despite Azar’s praise for the blueprint, however, administration policies derived from it have encountered setbacks. Last month, a federal judge in Washington struck down a rule that HHS had implemented in May that would have required drugmakers to include list prices of medications in drug ads, setting up a potential battle in the Supreme Court. A few days later, it was reported that the administration had withdrawn a proposal to crack down on rebates that drugmakers offer to pharmacy benefit managers by removing their safe-harbor protection under anti-kickback laws.
Meanwhile, in addition to opposition from the pharmaceutical industry, experts have expressed skepticism about how much the administration would be able to accomplish on its own without congressional action, while also stating that its proposals did not go to the heart of factors that actually drive drug costs.
Photo: Mark Wilson, Getty Images